Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 1 trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.

Oruka Therapeutics Inc.

Oruka Therapeutics, Inc. ( ($ORKA) ) has released its Q3 earnings. Here is a breakdown of the information Oruka Therapeutics, Inc. presented to its...

Market Cap	$1.49B	P/E Ratio	N/A
52W High	$31.80	52W Low	$5.49
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	75.4%	52W Position	93.8%
Overall Score	60	Value Score	60
Quality Score	55	Technical Score	66

EPS Current Est	$-2.15	EPS Next Est	$-2.45
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ORKA	$30.18	-0.10%	697.84K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ORKA	$30.18	-0.1%	697.84K
3
4
5
6

ORKA

ORKA

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Oruka Therapeutics Inc. Data in Excel

Get Oruka Therapeutics Inc. Data in Excel